



U.S. Pharmaceuticals
Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755

U.S. Pharmaceuticals

April 2010

Subject: Nitrostat® (nitroglycerin tablets, USP) 0.3 mg, 0.4 mg, and 0.6 mg availability

Dear Healthcare Provider:

On March 16, 2010 the FDA issued Warning Letters to suppliers of unapproved nitroglycerin sublingual tablets, requesting that they cease manufacturing and distribution of the products.

Pfizer's Nitrostat® (nitroglycerin tablets, USP) received FDA approval in 2000 and is currently the only brand of nitroglycerin sublingual tablets on the market.

Patient health and drug quality are top priorities at Pfizer and we are committed to supplying patients with the medicines they need. In response to a request from the FDA, Pfizer accelerated production of all 3 strengths of Nitrostat® (nitroglycerin tablets, USP) and now has additional inventory to meet the increased demand arising from the FDA's recent actions regarding unapproved nitroglycerin sublingual tablets. If you have difficulty ordering Nitrostat® from your primary wholesaler, please contact Pfizer Customer Service at 1-800-533-4535.

For any further information related to the removal of unapproved suppliers, please refer to the press releases posted on the FDA Website at:

<http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm204546.htm>

<http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm204540.htm>

Please see the enclosed full Prescribing Information for Nitrostat®. If you have any medical inquiries regarding Nitrostat®, please contact **Pfizer Medical Information at 1-800-438-1985**.

Sincerely,
Angela Hwang
Vice President, US Established Brands
Pfizer Inc
235 East 42nd St
New York, NY 10017

Robert Wolkow MD, FAAFP
Senior Medical Director
Pfizer Inc
235 East 42nd St
New York, NY 10017